论文部分内容阅读
近年来,半胱氨酰白三烯(Cys LT)受体拮抗剂在哮喘防治中的地位日益受到重视,目前已上市的有扎鲁司特、普仑司特及孟鲁司特钠,其中孟鲁司特钠具有高选择性,能竞争性拮抗白三烯D4(LTD4)与Cys LT1受体的结合。近年的研究发现其不仅能扩张气道,改善哮喘患者肺功能、而且还有抗炎作
In recent years, cysteinyl leukotriene (Cys LT) receptor antagonist in the prevention and treatment of asthma in the status of increasingly attention, there are currently listed zalrukte, pranlukast and montelukast sodium, which Montelukast sodium is highly selective and competitively antagonizes the binding of leukotriene D4 (LTD4) to the Cys LT1 receptor. Recent studies have found that it can not only expand the airway, improve lung function in patients with asthma, but also anti-inflammatory